Nice to see the one thumbs down....(Looks like Hoffman frequents this message board.)
The arrogance of these people can be smelled through the internet...
Yep: another position that just slipped his mind: How stupid are we?????
Eric Hoffman, PhD., CEO
Dr. Hoffman is a human molecular geneticist with extensive experience in translational therapeutics in the muscular dystrophies. He is co-founder of ReveraGen, and Agada Biosciences. Working with Louis Kunkel at Boston Children’s Hospital, Dr. Hoffman helped clone the Duchenne muscular dystrophy gene. He then identified dystrophin, and its deficiency as the cause of Duchenne muscular dystrophy. He has made key contributions to the genetics and genomics and molecular diagnostics of many types of neuromuscular disease. He currently holds the A James Clark Chair in Molecular Medicine at Children’s National Medical Center, where he leads the Center for Genetic Medicine Research. He is Professor and Chair of the Department of Integrative Systems Biology at George Washington University School of Medicine. Dr. Hoffman serves on the Scientific Advisory Boards of Foundation to Eradicate Duchenne, CureDuchenne, Crystal Ball for a Cure, and C3 Foundation. He is President-elect of the TREAT-NMD international network, and Scientific Director of the Cooperative International Neuromuscular Disease Research Group (CINRG). He has over 500 publications, and holds 7 patents.
"The only companies that contested the methodology for dystrophyn production were those
whose medicines, didn't generate any."
Oh, yeah, for those who don't know:: Agada Biosciences == Hoffman
So basically, Hoffman has muddied the regulatory waters to the extent that the assay methodology used
to measure dystrophin production should be restarted from scratch for all the trials, so the newer
technique, proposed by Agada Biosciences called mass spectrometry, can be used to document
patient progress. This, by the way, would create a reset in the past, and current ongoing studies,
with further delays...
Inquiring minds ask, Is this in the best interest of DMD patients?
It's all about the money. CG is right to resign, Hoffman and Co are pieces of #$%$ o l a"
as are the RNA/Biolmartin and PTCT crowd.
Sentiment: Strong Buy
only if each company had different management than the current one. arna could just retain a portion
of the companies, and let each one incentivize and market...
eh, nubie here in tjx, who is Myerowitz and what is wrong with the EU?
(Note the currency exchange rate for the $ / euro..)
A gay boy had a tiff and killed all in a moment of depression. very sad, for all.